NCT03437785

Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 Tablet

A Phase 2, Multi-center, Randomized, Double-blind, Parallel-group Trial to Evaluate the Efficacy and Safety of CKD-495 in Patients With Acute and Chronic Gastritis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 250 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

To Evaluate the Efficacy and Safety of CKD-495

Detailed description

A Phase 2, Multi-center, Randomized, Double-blind, Parallel-group Trial to Evaluate the Efficacy and Safety of CKD-495 in Patients with Acute and Chronic Gastritis

Conditions

• Gastritis

Interventions

Type	Name	Description
DRUG	CKD-495 75mg	CKD-495 75mg Tab.
DRUG	CKD-495 150mg	CKD-495 150mg Tab.
DRUG	Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg	Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.
DRUG	Rebamipide 100mg	Rebamipide 100mg Tab.
DRUG	Placebo of the CKD-495 75mg	Placebo of the CKD-495 75mg Tab.
DRUG	Placebo of the CKD-495 150mg	Placebo of the CKD-495 150mg Tab.
DRUG	Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg	Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
DRUG	Placebo of the Rebamipide 100mg	Placebo of the Rebamipide 100mg Tab

Timeline

• Start date: 2018-01-16
• Primary completion: 2018-10-12
• Completion: 2018-10-12
• First posted: 2018-02-19
• Last updated: 2018-10-31

Locations

16 sites across 1 country: South Korea